Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study

Background/Aims: Escherichia coli Nissle 1917 (EcN) alone therapy is as effective as mesalamine in inducing and maintaining remission in ulcerative colitis (UC). The efficacy and safety of EcN in combination with standard therapies have not been studied. This study examined the changes in the inflam...

Full description

Bibliographic Details
Main Authors: Gyu Man Oh, Won Moon, Kwang Il Seo, Kyoungwon Jung, Jae Hyun Kim, Sung Eun Kim, Moo In Park, Seun Ja Park
Format: Article
Language:English
Published: Jin Publishing & Printing Co. 2021-01-01
Series:The Korean Journal of Gastroenterology
Subjects:
Online Access:http://www.kjg.or.kr/journal/view.html?uid=5659&vmd=Full
_version_ 1819297440131448832
author Gyu Man Oh
Won Moon
Kwang Il Seo
Kyoungwon Jung
Jae Hyun Kim
Sung Eun Kim
Moo In Park
Seun Ja Park
author_facet Gyu Man Oh
Won Moon
Kwang Il Seo
Kyoungwon Jung
Jae Hyun Kim
Sung Eun Kim
Moo In Park
Seun Ja Park
author_sort Gyu Man Oh
collection DOAJ
description Background/Aims: Escherichia coli Nissle 1917 (EcN) alone therapy is as effective as mesalamine in inducing and maintaining remission in ulcerative colitis (UC). The efficacy and safety of EcN in combination with standard therapies have not been studied. This study examined the changes in the inflammation markers and symptoms following the additional administration of EcN to patients showing the clinical remission of UC. Methods: UC patients who received EcN after being in clinical remission for more than 3 months at Kosin University Gospel Hospital between 2013 and 2018 were evaluated through the retrospective medical-record-based review. The partial Mayo score, fecal calprotectin (FC), BMI, hemoglobin, serum cholesterol, serum albumin levels, and the safety profiles were examined at 3rd and 6th months after initiating EcN. Results: Ninety-four patients were included. After 3 months of treatment, there was no significant change in FC (156.3 μg/g to 141.1 μg/g) (p=0.653). On the other hand, partial Mayo score decreased significantly from 0.085 to 0.014 (p=0.025), and the bodyweight (p=0.001), BMI (p<0.001), hemoglobin (p=0.009), and cholesterol level increased (p=0.148). One patient (1.1%) experienced a serious adverse event with UC flare-up, and 14 patients (14.9%) discontinued EcN due to adverse events; all developed within 3 months. Conclusions: Additional administration of EcN to clinically remission-attained UC patients may improve the UC symptoms without changing the FC levels. EcN-associated adverse events develop within the early few weeks.
first_indexed 2024-12-24T05:14:02Z
format Article
id doaj.art-61ec0f6fc6904d0595217f4a2d99cac1
institution Directory Open Access Journal
issn 1598-9992
2233-6869
language English
last_indexed 2024-12-24T05:14:02Z
publishDate 2021-01-01
publisher Jin Publishing & Printing Co.
record_format Article
series The Korean Journal of Gastroenterology
spelling doaj.art-61ec0f6fc6904d0595217f4a2d99cac12022-12-21T17:13:36ZengJin Publishing & Printing Co.The Korean Journal of Gastroenterology1598-99922233-68692021-01-01771122110.4166/kjg.2020.0119Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort StudyGyu Man Oh0Won Moon1https://orcid.org/0000-0002-3963-8680Kwang Il Seo2Kyoungwon Jung3Jae Hyun Kim4Sung Eun Kim5Moo In Park6Seun Ja Park7Department of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaBackground/Aims: Escherichia coli Nissle 1917 (EcN) alone therapy is as effective as mesalamine in inducing and maintaining remission in ulcerative colitis (UC). The efficacy and safety of EcN in combination with standard therapies have not been studied. This study examined the changes in the inflammation markers and symptoms following the additional administration of EcN to patients showing the clinical remission of UC. Methods: UC patients who received EcN after being in clinical remission for more than 3 months at Kosin University Gospel Hospital between 2013 and 2018 were evaluated through the retrospective medical-record-based review. The partial Mayo score, fecal calprotectin (FC), BMI, hemoglobin, serum cholesterol, serum albumin levels, and the safety profiles were examined at 3rd and 6th months after initiating EcN. Results: Ninety-four patients were included. After 3 months of treatment, there was no significant change in FC (156.3 μg/g to 141.1 μg/g) (p=0.653). On the other hand, partial Mayo score decreased significantly from 0.085 to 0.014 (p=0.025), and the bodyweight (p=0.001), BMI (p<0.001), hemoglobin (p=0.009), and cholesterol level increased (p=0.148). One patient (1.1%) experienced a serious adverse event with UC flare-up, and 14 patients (14.9%) discontinued EcN due to adverse events; all developed within 3 months. Conclusions: Additional administration of EcN to clinically remission-attained UC patients may improve the UC symptoms without changing the FC levels. EcN-associated adverse events develop within the early few weeks.http://www.kjg.or.kr/journal/view.html?uid=5659&vmd=Fullinflammatory bowel diseasescolitisulcerativeprobioticsprebiotics
spellingShingle Gyu Man Oh
Won Moon
Kwang Il Seo
Kyoungwon Jung
Jae Hyun Kim
Sung Eun Kim
Moo In Park
Seun Ja Park
Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study
The Korean Journal of Gastroenterology
inflammatory bowel diseases
colitis
ulcerative
probiotics
prebiotics
title Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study
title_full Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study
title_fullStr Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study
title_full_unstemmed Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study
title_short Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study
title_sort therapeutic potential of escherichia coli nissle 1917 in clinically remission attained ulcerative colitis patients a hospital based cohort study
topic inflammatory bowel diseases
colitis
ulcerative
probiotics
prebiotics
url http://www.kjg.or.kr/journal/view.html?uid=5659&vmd=Full
work_keys_str_mv AT gyumanoh therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy
AT wonmoon therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy
AT kwangilseo therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy
AT kyoungwonjung therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy
AT jaehyunkim therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy
AT sungeunkim therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy
AT mooinpark therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy
AT seunjapark therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy